Substrate In Vitro Evidence:
1. Transient transfection of ABCB6 promoter constructs containing the luciferase gene resulted in an 1100-2300-fold increase compared to empty vector. Further experiments demonstrated that the promoter is orientation-dependent. Emadi-Konjin, HP et al. Biochim Biophys Acta 2002 Mar 19, 1574(2):117-30 PMID 11955620.
Substrate In Vivo Evidence:
1. MTABC3 (mammalian mitochondrial ABC protein 3) is a half-transporter that transfer a precursor of the iron-sulfur cluster from mitochondria to the cytosol in yeast. The 2q36 region is within the candidate locus for lethal neonatal metabolic syndrome, a disorder of mitochondrial function associated with iron metabolism. Mitsuhashi, N et al. JBC 2000 Jun 9, 275(23):17536-40 PMID 10837493.
2. ABCB6 is not the causative gene for the growth retardation syndrome with amindoaciduria, cholestasis, iron overload, and lactacidosis (GRACILE). No mutations in the ABCB6 coding region were found, and expression level in fibroblasts were comparable between patients and controls. Vispaa, I et al. Am J Med Genet 2002 May 1, 109(3):202-5 PMID 11977179.
Tissue Distribution Evidence:
1. Northern blots demonstrate that ABCB6 is expressed ubiquitously, but at low levels in normal human liver. ABCB6 is overexpressed in human hepatocellular carcinomas compared to paired surrounding non-malignant tissue. Emadi-Konjin, HP et al. Biochim Biophys Acta 2002 Mar 19, 1574(2):117-30 PMID 11955620.
Transmembrane prediction: Non-synonymous amino acid changes shown in red, indels (insertions and deletions) in blue, and synonymous changes in green. Exon(s) indicated by black outlines.
Copyright 2009, UCSF Pharmacogenetics of Membrane Transporters. All rights reserved.
